AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PAINCHEK LTD

0.210

-0.015-6.67%

Volume:253.55K

Turnover:54.27K

Market Cap:43.85M

PE:-4.76

High:0.235

Open:0.235

Low:0.205

Close:0.225

52wk High:1.050

52wk Low:0.205

Shares:208.81M

Float Shares:151.37M

Volume Ratio:1.11

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.044

EPS(LYR):-0.044

ROE:-8647.59%

ROA:-151.46%

PB:-39.40

PE(LYR):-4.76

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

PainChek's Annual Recurring Revenue Grows to AU$4 Million as of January-End

MT Newswires Live

PainChek Says Independent Legal Opinion Confirms Its Device Qualifies For US Remote Therapeutic Monitoring Reimbursement Claims

MT Newswires Live

BRIEF-PainChek Secures First US Customer After FDA Clearance

Should FDA De Novo Clearance for Adult App Prompt a Rethink by PainChek (ASX:PCK) Investors?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PCK.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PCK.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PCK.AU\",,,,,undefined,":{"symbol":"PCK.AU","market":"AU","secType":"STK","nameCN":"PAINCHEK LTD","latestPrice":0.21,"timestamp":1770354720000,"preClose":0.225,"halted":0,"volume":253545,"delay":0,"changeRate":-0.06666666666666672,"nameEN":"PAINCHEK LTD","floatShares":151372384,"shares":208806066,"eps":-0.044164,"marketStatus":"Market Closed","change":-0.015,"latestTime":"02-06 16:12:00 AEDT","open":0.235,"high":0.235,"low":0.205,"amount":54267,"amplitude":0.133333,"askPrice":0.22,"askSize":109988,"bidPrice":0.205,"bidSize":24985,"shortable":3,"etf":0,"ttmEps":-0.044164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.225,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":1.1080379009433212,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PCK.AU\",,,,,undefined,":{"symbol":"PCK.AU","floatShares":151372384,"roa":"-151.46%","roe":"-8647.59%","lyrEps":-0.044164,"volumeRatio":1.1080379009433212,"shares":208806066,"dividePrice":0,"high":0.235,"amplitude":0.133333,"preClose":0.225,"low":0.205,"week52Low":0.205,"pbRate":"-39.40","psRate":"13.04","week52High":1.05,"institutionHeld":0,"latestPrice":0.21,"committee":-0.629778,"eps":-0.044164,"divideRate":0,"volume":253545,"delay":0,"ttmEps":-0.044164,"open":0.235,"prevYearClose":0.29,"prevWeekClose":0.255,"prevMonthClose":0.255,"prevQuarterClose":0.29,"fiveDayClose":0.255,"twentyDayClose":0.285,"sixtyDayClose":0.46,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PCK.AU\",params:#limit:5,,,undefined,":[{"date":"2026-01-29","symbol":"PCK.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1769641200000,"name":null,"time":"Pre-Market","dateTimestamp":1769605200000,"actualEps":null},{"market":"AU","date":"2025-11-28","symbol":"PCK.AU","defaultRemindTime":1764284400000,"type":"split","dateTimestamp":1764248400000,"forFactor":10,"toFactor":1,"ratio":10},{"date":"2025-10-30","symbol":"PCK.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761778800000,"name":null,"time":"Pre-Market","dateTimestamp":1761742800000,"actualEps":null},{"date":"2025-07-31","symbol":"PCK.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753920000000,"name":null,"time":"Pre-Market","dateTimestamp":1753884000000,"actualEps":null},{"date":"2025-04-30","symbol":"PCK.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745971200000,"name":null,"time":"","dateTimestamp":1745935200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PCK.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PCK.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607064286","title":"PainChek's Annual Recurring Revenue Grows to AU$4 Million as of January-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2607064286","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607064286?lang=en_us&edition=fundamental","pubTime":"2026-01-30 11:28","pubTimestamp":1769743716,"startTime":"0","endTime":"0","summary":"PainChek  said its annual recurring revenue grew to AU$4 million at the end of January with the implementation of licenses, and it anticipates an annual recurring revenue of AU$5.6 million after all licenses have been implemented, according to a Friday Australian bourse filing.The company also has a pipeline for about AU$1.9 million in annual recurring revenue under negotiation across US, Canada, UK, and Australia-New Zealand, the filing said.The company plans to continue negotiating with the Centers for Medicare & Medicaid Services in the US for an additional specific PainChek Current Procedural Terminology reimbursement code by April, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PCK.AU","BK7094"],"gpt_icon":0},{"id":"2607194774","title":"PainChek Says Independent Legal Opinion Confirms Its Device Qualifies For US Remote Therapeutic Monitoring Reimbursement Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2607194774","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607194774?lang=en_us&edition=fundamental","pubTime":"2026-01-29 13:01","pubTimestamp":1769662880,"startTime":"0","endTime":"0","summary":"PainChek  said US healthcare law firm Nixon Law Group confirmed the PainChek device qualifies as a US Food and Drug Administration -regulated medical device for the purposes of Remote Therapeutic Monitoring  reimbursement claims in the US to the Centers for Medicare & Medicaid Services, according to a Thursday Australian bourse filing.The legal opinion confirmed that PainChek meets the statutory definition of a medical device under the US Federal Food, Drug, and Cosmetic Act and was granted De Novo classification by the FDA.Its device allows for assessing pain in non-verbal dementia patients in long-term care settings with musculoskeletal issues.The firm said it now operated two business models in the US, an existing business-to-business software-as-a-service offering to long-term care facilities, as well as a new RTM reimbursement model. It will formally launch its RTM initiative to customers and partners at HIMSS 2026 Global Health Conference in Las Vegas in March.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTM","BK7094","PCK.AU"],"gpt_icon":0},{"id":"2575444043","title":"BRIEF-PainChek Secures First US Customer After FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2575444043","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575444043?lang=en_us&edition=fundamental","pubTime":"2025-10-13 09:24","pubTimestamp":1760318680,"startTime":"0","endTime":"0","summary":"BRIEF-PainChek Secures First US Customer After FDA ClearanceOct 13 (Reuters) - PainChek Ltd PCK.AX:SECURES FIRST US CUSTOMER AFTER FDA CLEARANCEFurther company coverage: PCK.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VR2VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7094","PCK.AU"],"gpt_icon":0},{"id":"2574439349","title":"Should FDA De Novo Clearance for Adult App Prompt a Rethink by PainChek (ASX:PCK) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574439349","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574439349?lang=en_us&edition=fundamental","pubTime":"2025-10-11 10:19","pubTimestamp":1760149152,"startTime":"0","endTime":"0","summary":"PainChek has received De Novo clearance from the US FDA for its Adult App, authorizing it as the first regulated medical device for pain assessment in individuals who cannot reliably self-report, including those with dementia, thus unlocking access to the US aged care market.\nThe clearance not only enables immediate US commercial rollout but also paves the way for expanded opportunities in international markets that recognize FDA data standards, such as Japan and Germany.\nWe'll now explore...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pck/painchek-shares/news/should-fda-de-novo-clearance-for-adult-app-prompt-a-rethink","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pck/painchek-shares/news/should-fda-de-novo-clearance-for-adult-app-prompt-a-rethink","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCK.AU","BK7094","ISBC","BK4211","PCK"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PCK.AU\",params:#limit:6,delay:true,,,undefined,":[]}}